Best Ideas 2018 features all the nominated entries submitted to the Youth Citizen Entrepreneurship Competition under ‘Submit your Idea’ category. All the entries consist of innovative solution or proposition for an enterprise that champions the Sustainable Development Goals. They can be on the conceptual, planning, or start-up stage. If you want to know the 10 finalists in this category, click HERE
Explain your idea in details:
Goal: To develop a therapeutic ncRNA (resemble our genetic material) coated with lipid nanoparticles to mimic our cell membrane. The nanoparticles are then conjugated to antibodies for selective killing of diseased cancer cells. Objectives: 1- ncRNAs will be synthesized by Solid Phase Synthesis or Solid support techniques, then validation will be performed using HPLC-MS, northern blot and sequencing. Using various miRNAs to test our efficiency will take at least six months to one year. 2- Within five years we wish to establish our first mini-cell model so that we can start pre-clinical trials. Then two years later, we hope to start clinical trials and finish it within 10 years. Activities: *For mini-cell: Non-coding RNAs will be synthesized either by soluble support or solid phase synthesis techniques, Which are then screened by HPLC, sequencing techniques, northern blot, spectrophotometry and nanodrop. Once validated, RNAs are coated with lipid nanoparticles using microspray. Finally, nanoparticles of appropriate particle size are linked to anti-body. At last, nanoparticles are mixed with excipients to formulate Mini-cell. Innovation Points: the use of RNA interference therapy is a highly promising therapy with 164,000 papers are published to date. Furthermore, Mini-cell formula is a targeted therapy for cancer, as the nanoparticles are conjugated to antibodies for selective killing of diseased cells. Consequently, this will benefit the patients as detrimental chemotherapy side effects are avoided. Also, the product is long acting and so better patient compliance. Lastly, Mini-cell will be formulated either as SC or IM, therefore no need complicated IV procedures.
Expected impact of your idea on sustainable development
Our main target is breast cancer, which is one of the most aggressive diseases, ranked as the second most common cancer in women with nearly 1.7 million cases diagnosed in 2012 and approximately 15% mortality rate. It is a global problem as incidence rates vary from 19.3 per 100,000 women in Eastern Africa to 89.7 per 100,000 women in Western Europe. The major problems are the late diagnosis of breast cancer and the detrimental side effects of chemotherapy and radiotherapy. Consequently, this calls for new therapy Short term (current year): • Testing the productivity (efficacy and efficiency) of our model for synthesis of 50-100 ncRNA with high therapeutic potential (eg.hsa-miR-122) • Testing the productivity (efficacy and efficiency) of our model for primer synthesis for diagnosis of genes characteristic for cancer cells (eg. ABL-BCR in Leukemia) Medium term (next 1 – 2 years): • Start selling nc RNAs and primers (10% revenues) • Start working on mini-cell prototype Long term (3 years and beyond): • Optimized mini-cell model so that we can start pre-clinical trials • Then 2 years later, we wish to start clinical trials hoping they can be accomplished in 10 years
Plans for implementation and sustainability
Mini-cell is a therapeutic ncRNA (resemble our genetic material) coated with lipid nanoparticles to mimic our cell membrane. The nanoparticles are then conjugated to antibodies for selective killing of diseased cells. As a first phase, we are planning to sell nc-RNAs and primers to be used for research and diagnostics, where the revenues will be used to support research and development of our main product *For primers: Firstly, bioinformatics analysis will be done on gene sequence for primer design. Then, primers will be synthesized either by soluble support or solid phase synthesis techniques, which are then screened by HPLC, sequencing techniques, northern blot, spectrophotometry and nanodrop device. Once validated, they are prepared for the customer for research and diagnostics purposes. *For non-coding RNAs: RNAs will be synthesized either by soluble support or solid phase synthesis techniques, which are then screened by HPLC, sequencing techniques, northern blot, spectrophotometry and nanodrop. Once validated, they are prepared for the customer to use in research and diagnostics
Age: 24 , DOB: 20/09/1993 Qualifications and education: *Masters of Business Administration, Brooklyn Business School: 2018-2019 *Masters of Science, Pharmacology and Toxicology, German University in Cairo: 2017-2018 *Bachelor of Science, Pharmacology and Toxicology, German University in Cairo: 2011-2016 Previous work experience: *Lab specialist, National Organization for Research and Control of Biologicals (01/2018-now) *Graduate intern, LMU-Pharmaceutical Biology (07/2017-08/2017) *Undergraduate intern, Cologne University Hospital, Institute for Pathology (07/2015-08/2015) Training: *Pharma innovation weekend, winter 2017 *PCR workshop, summer 2016 *Enter the world of research workshop, summer 2016 *Molecular biology workshop, winter 2015 *5357 hospital workshop, summer 2014 *Nanotechnology workshop, winter 2011 Motivation: For various reasons,where I am passionate for research and accordingly setting up my own business will hopefully fill bench to market gap as research findings are translated into products. Finally, as Mahatma Ghandi said:"Be the change you want to see" and so nothing is better than transforming medical research into a new promising therapy that can beat challenging diseases such as cancer, with better efficacy and quality of life compared to conventional therapy in addition to lower cost.